Vascular anomalies

Main Article Content

Luísa Ciucci Biagioni
https://orcid.org/0000-0003-2695-8519

Abstract

Vascular anomalies are complex diseases with different clinical presentations. In ancient times, some purplish spots were already seen as a curse, and over the centuries, they began to be described as part of other diseases, gaining different eponyms. In recent decades, the term "hemangioma" has been missused to describe a large part of vascular anomalies, causing a significant problem in diagnosing and treating patients.



Article Details

How to Cite
1.
Biagioni LC. Vascular anomalies. HSJ [Internet]. 2022 Jun. 25 [cited 2024 Nov. 4];12(2):1-2. Available from: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1266
Section
EDITORIAL
Author Biography

Luísa Ciucci Biagioni, Centro Paulista de Anomalias Vasculares, Hospital Santa Marcelina, Vasculine

Graduation in Medicine from the School of Health Sciences ESCS/DF. Medical residency in general, vascular and endovascular surgery at Hospital Santa Marcelina SP. Specialist in vascular surgery SBACV/AMB. Area of expertise in Vascular Ultrasound by SBACV/CBR. Member of the International Society for The Study for Vascular Anomalies ISSVA. Master in Health Sciences from Hospital Israelita Albert Einstein.

References

Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412-22. https://doi.org/10.1097/00006534-198203000-00002

Carqueja IM, Sousa J, Mansilha A. Vascular malformations: classification, diagnosis and treatment. Int Angiol. 2018;37(2):127-42. https://doi.org/10.23736/S0392-9590.18.03961-5

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-51. https://doi.org/10.1056/NEJMc0708819

Gu H, Liu H, Cai R, Chen H, Lin X. Managing vascular anomalies in the era of genetics and precision medicine: an opportunity or a challenge? Ann Plast Surg. 2021;86(3S Suppl 2):S269-72. https://doi.org/10.1097/SAP.0000000000002723

Le Cras TD, Goines J, Lakes N, Pastura P, Hammill AM, Adams DM, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis. 2020;23(3):425-42. https://doi.org/10.1007/s10456-020-09722-0

Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257. https://doi.org/10.1542/peds.2015-3257

Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. J Vasc Surg. 202071(1):318-27. https://doi.org/10.1016/j.jvs.2019.06.217

Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-6. https://doi.org/10.1038/s41586-018-0217-9

Eifert S, Villavicencio JL, Kao TC, Taute BM, Rich NM. Prevalence of deep venous anomalies in congenital vascular malformations of venous predominance. J Vasc Surg. 2000;31(3):462-71. PMID: 10709058